Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Marcocci

Showing results (131-140 of 209) with videos related to

Pageof 21
Sort By:
Calcified Tissue International|October 24, 2008
Intramuscular neridronate in postmenopausal women with low bone mineral densitySilvano Adami, Davide Gatti, Francesco Bertoldo, et al.
The Journal of Clinical Endocrinology and Metabolism|December 22, 2022
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice GuidelineGhada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu, et al.
Endocrine Reviews|October 16, 2018
Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding QuestionsRoger Bouillon, Claudio Marcocci, Geert Carmeliet, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 26, 2018
A rapid screening of a recurrent CYP24A1 pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH)Elisa De Paolis, Angelo Minucci, Maria De Bonis, et al.
Thyroid : Official Journal of the American Thyroid Association|October 18, 2012
Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfactionRoberto Rocchi, Riccardo Lenzi, Michele Marinò, et al.
Frontiers in Endocrinology|July 24, 2023
Cutaneous lesions and other non-endocrine manifestations of Multiple Endocrine Neoplasia type 1 syndromeLaura Pierotti, Elena Pardi, Elisa Dinoi, et al.
Thyroid : Official Journal of the American Thyroid Association|January 17, 2018
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional StudyElena Sabini, Barbara Mazzi, Maria Antonietta Profilo, et al.
European Journal of Endocrinology|February 10, 2015
Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological studyEleonora Sisti, Barbara Coco, Francesca Menconi, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2003
Long-term safety of orbital radiotherapy for Graves' ophthalmopathyClaudio Marcocci, Luigi Bartalena, Roberto Rocchi, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 13, 2016
VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPYMarenza Leo, Teresa Mautone, Ilaria Ionni, et al.
Pageof 21

Showing results (131-140 of 209) with videos related to

Sort By:
Pageof 21
Calcified Tissue International|October 24, 2008
Intramuscular neridronate in postmenopausal women with low bone mineral densitySilvano Adami, Davide Gatti, Francesco Bertoldo, et al.
The Journal of Clinical Endocrinology and Metabolism|December 22, 2022
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice GuidelineGhada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu, et al.
Endocrine Reviews|October 16, 2018
Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding QuestionsRoger Bouillon, Claudio Marcocci, Geert Carmeliet, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 26, 2018
A rapid screening of a recurrent CYP24A1 pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH)Elisa De Paolis, Angelo Minucci, Maria De Bonis, et al.
Thyroid : Official Journal of the American Thyroid Association|October 18, 2012
Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfactionRoberto Rocchi, Riccardo Lenzi, Michele Marinò, et al.
Frontiers in Endocrinology|July 24, 2023
Cutaneous lesions and other non-endocrine manifestations of Multiple Endocrine Neoplasia type 1 syndromeLaura Pierotti, Elena Pardi, Elisa Dinoi, et al.
Thyroid : Official Journal of the American Thyroid Association|January 17, 2018
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional StudyElena Sabini, Barbara Mazzi, Maria Antonietta Profilo, et al.
European Journal of Endocrinology|February 10, 2015
Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological studyEleonora Sisti, Barbara Coco, Francesca Menconi, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2003
Long-term safety of orbital radiotherapy for Graves' ophthalmopathyClaudio Marcocci, Luigi Bartalena, Roberto Rocchi, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 13, 2016
VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPYMarenza Leo, Teresa Mautone, Ilaria Ionni, et al.
Pageof 21